A Phase 2 interventional study of TERN-501 and TERN-101 in NASH - Nonalcoholic Steatohepatitis, sponsored by Terns, Inc.. Completed at 35 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2025-03-12.
Sponsored by Terns, Inc. (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc — none open to participants now, none under way, none of them phase 3. Non-alcoholic Fatty Liver Disease · Merck & Co., Inc.
Among the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc, this one is the 3rd largest by enrollment of the 10 interventional ones that give a count, is the only one that started in 2022, is one of 7 in phase 2, and was the 7th registered.
1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.
Browse Non-alcoholic Fatty Liver Disease studies →None of the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc is open now. The open studies under Non-alcoholic Fatty Liver Disease, anywhere →
Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 162 is above the median of 60 across 1,176 interventional studies indexed under Non-alcoholic Fatty Liver Disease.
Median enrollment 113 across the 10 interventional studies, 10 across the 1 observational. Of the 11 that completed or were terminated, 8 (73%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Terns, Inc., one of the names counted as Merck & Co., Inc. Under that name alone:
Terns, Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Non-alcoholic Fatty Liver Disease by Merck & Co., Inc, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a Phase 2a Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Orally Administered TERN-501 as Monotherapy as well as in Combination with TERN-101 in Noncirrhotic Adults with Presumed Non-Alcoholic Steatohepatitis (NASH)
Key Inclusion Criteria:
Key Exclusion Criteria:
Other protocol-defined I/E criteria that apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Orally administered.
Drug: TERN-501
Orally administered.
Drug: TERN-501
Orally administered.
Drug: TERN-501
Orally administered.
Drug: TERN-501 · Drug: TERN-101
Orally administered.
Drug: TERN-501 · Drug: TERN-101
Orally administered.
Drug: TERN-101
Orally administered.
Other: Placebo
Investigational drug
Investigational drug
Matching placebo
Relative Change From Baseline in MRI-PDFF at Week 12 for TERN-501 Monotherapy (Arms 1, 2 and 3) Compared to Placebo.
Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) is a non-invasive imaging technique that measures fat content in tissue, particularly in the liver. Relative change from baseline is calculated for each subject as 100 x \[(Week 12 Value - Baseline Value)/Baseline Value\].
Time frame: 12 weeks
Change From Baseline in cT1 Relaxation Time at Week 12 for TERN-501 Monotherapy (Arms 1, 2 and 3) Compared to Placebo
Corrected T1 (cT1) is a quantitative MRI relaxation parameter that measures liver inflammation and fibrosis. Change from baseline is calculated for each subject as (Week 12 Value - Baseline Value).
Time frame: 12 weeks
Relative Change From Baseline in MRI-PDFF at Week 12 for TERN-501+TERN-101 Combination (Arms 4 and 5) Compared to Placebo
Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) is a non-invasive imaging technique that measures fat content in tissue, particularly in the liver. Relative change from baseline is calculated for each subject as 100 x \[(Week 12 Value - Baseline Value)/Baseline Value\].
Time frame: 12 weeks
Change From Baseline in cT1 Relaxation Time at Week 12 for TERN-501+TERN-101 Combination (Arms 4 and 5) Compared to Placebo
Corrected T1 (cT1) is a quantitative MRI relaxation parameter that measures liver inflammation and fibrosis. Change from baseline is calculated for each subject as (Week 12 Value - Baseline Value).
Time frame: 12 weeks
Number and Percentage of Participants With Any Treatment Emergent Adverse Event for All Treatment Groups (Threshold of 0%)
This outcome measures the number and percentage of participants with any Treatment Emergent Adverse Event (TEAE) for All Treatment Groups (0% Threshold). TEAEs by System Organ Class and Preferred Term meeting the 5% Threshold are reported in the Other Adverse Events section.
Time frame: 16 weeks
| Milestone | Arm 1: TERN-501 1 mg | Arm 2: TERN-501 3 mg | Arm 3: TERN-501 6 mg | Arm 4: TERN-501 3 mg + TERN-101 10 mg | Arm 5: TERN-501 6 mg + TERN-101 10 mg | Arm 6:TERN-101 10 mg | Arm 7: Matching Placebo |
|---|---|---|---|---|---|---|---|
| Started | 23 | 23 | 22 | 23 | 23 | 24 | 24 |
| Treated | 23 | 23 | 22 | 23 | 23 | 24 | 24 |
| Discontinued treatment | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Completed | 23 | 20 | 22 | 19 | 21 | 23 | 21 |
| Not completed | 0 | 3 | 0 | 4 | 2 | 1 | 3 |
| Withdrew: Lost to follow-up | 0 | 2 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Protocol violation | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Sponsor discretion | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 1 | 0 | 1 | 1 | 0 | 1 |
Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) is a non-invasive imaging technique that measures fat content in tissue, particularly in the liver. Relative change from baseline is calculated for each subject as 100 x \[(Week 12 Value - Baseline Value)/Baseline Value\].
| Percent change from baseline | Arm 1: TERN-501 1 mg | Arm 2: TERN-501 3 mg | Arm 3: TERN-501 6 mg | Arm 7: Matching Placebo |
|---|---|---|---|---|
| Relative Change From Baseline in MRI-PDFF at Week 12 for TERN-501 Monotherapy (Arms 1, 2 and 3) Compared to Placebo. | -15.39 ± 5.186 | -27.48 ± 5.740 | -44.81 ± 5.856 | -4.01 ± 5.416 |
Corrected T1 (cT1) is a quantitative MRI relaxation parameter that measures liver inflammation and fibrosis. Change from baseline is calculated for each subject as (Week 12 Value - Baseline Value).
| msec | Arm 1: TERN-501 1 mg | Arm 2: TERN-501 3 mg | Arm 3: TERN-501 6 mg | Arm 7: Matching Placebo |
|---|---|---|---|---|
| Change From Baseline in cT1 Relaxation Time at Week 12 for TERN-501 Monotherapy (Arms 1, 2 and 3) Compared to Placebo | -28.2 ± 14.62 | -25.6 ± 15.71 | -72.0 ± 16.12 | 3.6 ± 14.92 |
Magnetic Resonance Imaging Proton Density Fat Fraction (MRI-PDFF) is a non-invasive imaging technique that measures fat content in tissue, particularly in the liver. Relative change from baseline is calculated for each subject as 100 x \[(Week 12 Value - Baseline Value)/Baseline Value\].
| Percent change from baseline | Arm 4: TERN-501 3 mg + TERN-101 10 mg | Arm 5: TERN-501 6 mg + TERN-101 10 mg | Arm 7: Matching Placebo |
|---|---|---|---|
| Relative Change From Baseline in MRI-PDFF at Week 12 for TERN-501+TERN-101 Combination (Arms 4 and 5) Compared to Placebo | -20.75 ± 5.713 | -47.74 ± 5.412 | -4.01 ± 5.416 |
Corrected T1 (cT1) is a quantitative MRI relaxation parameter that measures liver inflammation and fibrosis. Change from baseline is calculated for each subject as (Week 12 Value - Baseline Value).
| msec | Arm 4: TERN-501 3 mg + TERN-101 10 mg | Arm 5: TERN-501 6 mg + TERN-101 10 mg | Arm 7: Matching Placebo |
|---|---|---|---|
| Change From Baseline in cT1 Relaxation Time at Week 12 for TERN-501+TERN-101 Combination (Arms 4 and 5) Compared to Placebo | -59.0 ± 16.25 | -65.5 ± 14.99 | 3.6 ± 14.92 |
This outcome measures the number and percentage of participants with any Treatment Emergent Adverse Event (TEAE) for All Treatment Groups (0% Threshold). TEAEs by System Organ Class and Preferred Term meeting the 5% Threshold are reported in the Other Adverse Events section.
| Participants | Arm 1: TERN-501 1 mg | Arm 2: TERN-501 3 mg | Arm 3: TERN-501 6 mg | Arm 4: TERN-501 3 mg + TERN-101 10 mg | Arm 5: TERN-501 6 mg + TERN-101 10 mg | Arm 6:TERN-101 10 mg | Arm 7: Matching Placebo |
|---|---|---|---|---|---|---|---|
| Number and Percentage of Participants With Any Treatment Emergent Adverse Event for All Treatment Groups (Threshold of 0%) | 11 | 13 | 11 | 14 | 12 | 10 | 11 |
Collected over 16 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Arm 1: TERN-501 1 mg | 0/23 (0%) | 1/23 (4.3%) | 2/23 (8.7%) |
| Arm 2: TERN-501 3 mg | 0/23 (0%) | 0/23 (0%) | 8/23 (34.8%) |
| Arm 3: TERN-501 6 mg | 0/22 (0%) | 0/22 (0%) | 5/22 (22.7%) |
| Arm 4: TERN-501 3 mg + TERN-101 10 mg | 0/23 (0%) | 0/23 (0%) | 10/23 (43.5%) |
| Arm 5: TERN-501 6 mg + TERN-101 10 mg | 0/23 (0%) | 0/23 (0%) | 6/23 (26.1%) |
| Arm 6:TERN-101 10 mg | 0/24 (0%) | 2/24 (8.3%) | 5/24 (20.8%) |
| Arm 7: Matching Placebo | 0/24 (0%) | 0/24 (0%) | 5/24 (20.8%) |
| Event | Arm 1: TERN-501 1 mg | Arm 2: TERN-501 3 mg | Arm 3: TERN-501 6 mg | Arm 4: TERN-501 3 mg + TERN-101 10 mg | Arm 5: TERN-501 6 mg + TERN-101 10 mg | Arm 6:TERN-101 10 mg | Arm 7: Matching Placebo |
|---|---|---|---|---|---|---|---|
| PneumoniaInfections and infestations | 1/23 | 0/23 | 0/22 | 0/23 | 0/23 | 0/24 | 0/24 |
| CellulitisInfections and infestations | 0/23 | 0/23 | 0/22 | 0/23 | 0/23 | 1/24 | 0/24 |
| AnxietyPsychiatric disorders | 0/23 | 0/23 | 0/22 | 0/23 | 0/23 | 1/24 | 0/24 |
| Event | Arm 1: TERN-501 1 mg | Arm 2: TERN-501 3 mg | Arm 3: TERN-501 6 mg | Arm 4: TERN-501 3 mg + TERN-101 10 mg | Arm 5: TERN-501 6 mg + TERN-101 10 mg | Arm 6:TERN-101 10 mg | Arm 7: Matching Placebo |
|---|---|---|---|---|---|---|---|
| PruritusSkin and subcutaneous tissue disorders | 0/23 | 2/23 | 3/22 | 7/23 | 4/23 | 1/24 | 3/24 |
| DiarrhoeaGastrointestinal disorders | 1/23 | 5/23 | 2/22 | 2/23 | 0/23 | 1/24 | 1/24 |
| Upper respiratory tract infectionInfections and infestations | 1/23 | 0/23 | 1/22 | 3/23 | 0/23 | 2/24 | 0/24 |
| NasopharyngitisRespiratory, thoracic and mediastinal disorders | 0/23 | 1/23 | 2/22 | 0/23 | 0/23 | 1/24 | 0/24 |
| HeadacheGeneral disorders | 1/23 | 1/23 | 1/22 | 2/23 | 0/23 | 1/24 | 2/24 |
| NauseaGastrointestinal disorders | 0/23 | 2/23 | 1/22 | 1/23 | 2/23 | 0/24 | 0/24 |
Patients who were randomized and received at least 1 dose of study drug were included in the Efficacy Analysis Set
| Age, Categorical(Participants) | Arm 1: TERN-501 1 mg | Arm 2: TERN-501 3 mg | Arm 3: TERN-501 6 mg | Arm 4: TERN-501 3 mg + TERN-101 10 mg | Arm 5: TERN-501 6 mg + TERN-101 10 mg | Arm 6:TERN-101 10 mg | Arm 7: Matching Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 18 | 18 | 19 | 16 | 20 | 20 | 21 | 132 |
| >=65 years | 5 | 5 | 3 | 7 | 3 | 4 | 3 | 30 |
| Age, Continuous(years) | Arm 1: TERN-501 1 mg | Arm 2: TERN-501 3 mg | Arm 3: TERN-501 6 mg | Arm 4: TERN-501 3 mg + TERN-101 10 mg | Arm 5: TERN-501 6 mg + TERN-101 10 mg | Arm 6:TERN-101 10 mg | Arm 7: Matching Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Median | 56.0 (27 to 71) | 55.0 (25 to 73) | 53.0 (25 to 70) | 59.0 (32 to 73) | 56.0 (34 to 71) | 56.5 (21 to 72) | 53.5 (32 to 71) | 55.5 (21 to 73) |
| Sex: Female, Male(Participants) | Arm 1: TERN-501 1 mg | Arm 2: TERN-501 3 mg | Arm 3: TERN-501 6 mg | Arm 4: TERN-501 3 mg + TERN-101 10 mg | Arm 5: TERN-501 6 mg + TERN-101 10 mg | Arm 6:TERN-101 10 mg | Arm 7: Matching Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Female | 11 | 13 | 16 | 11 | 11 | 12 | 15 | 89 |
| Male | 12 | 10 | 6 | 12 | 12 | 12 | 9 | 73 |
| Ethnicity (NIH/OMB)(Participants) | Arm 1: TERN-501 1 mg | Arm 2: TERN-501 3 mg | Arm 3: TERN-501 6 mg | Arm 4: TERN-501 3 mg + TERN-101 10 mg | Arm 5: TERN-501 6 mg + TERN-101 10 mg | Arm 6:TERN-101 10 mg | Arm 7: Matching Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 17 | 13 | 15 | 11 | 14 | 10 | 19 | 99 |
| Not Hispanic or Latino | 6 | 10 | 7 | 12 | 9 | 14 | 5 | 63 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Arm 1: TERN-501 1 mg | Arm 2: TERN-501 3 mg | Arm 3: TERN-501 6 mg | Arm 4: TERN-501 3 mg + TERN-101 10 mg | Arm 5: TERN-501 6 mg + TERN-101 10 mg | Arm 6:TERN-101 10 mg | Arm 7: Matching Placebo | Total |
|---|---|---|---|---|---|---|---|---|
| White | 20 | 22 | 18 | 20 | 18 | 19 | 22 | 139 |
| Black or African American | 1 | 0 | 3 | 3 | 3 | 2 | 0 | 12 |
| American Indian or Alaska Native | 2 | 1 | 0 | 0 | 1 | 1 | 0 | 5 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 2 |
| Asian | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 1 |
| Not reported | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Other (Puerto Rican) | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2022 to primary completion in Jul 2023, 12 months.
Results were first posted in Mar 2025, 1 year 8 months after primary completion.
Of 132 industry-sponsored phase 2 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 30. This study's 12 months is below that.
Counting every sponsor, half of 185 studies reached it within 26 months; a quarter within 16 and three quarters within 36.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Non-alcoholic Fatty Liver Disease →